natgillin/translations-raw huggingface dataset:
There are no adequate data from the use of vildagliptin in pregnant women. 
Nema odgovarajućih podataka o primjeni vildagliptina u trudnica.
There is no experience of vildagliptin use in clinical trials in patients with NYHA functional class IV and therefore use is not recommended in these patients. 
Ne postoji iskustvo s primjenom vildagliptina u kliničkim ispitivanjima u bolesnika s IV. funkcijskim stupnjem prema NYHA pa se zbog toga primjena u tih bolesnika ne preporučuje.
If you forget to take Jalra 
Ako ste zaboravili uzeti Jalru
Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue Jalra. 
U bolesnika koji razviju žuticu ili druge znakove koji upućuju na poremećaj jetrene funkcije treba prekinuti liječenje Jalrom.
• 50 mg daily in the morning if you have moderate or severe kidney disease or if you are on dialysis. 
• 50 mg na dan, ujutro, ako imate umjerenu ili tešku bolest bubrega ili ako ste na dijalizi.
Some patients have had the following side effects while taking Jalra and insulin (with or without metformin): 
Neki su bolesnici imali sljedeće nuspojave kada su uzimali Jalru i inzulin (sa ili bez metformina):
Of these patients, 2,264 patients received vildagliptin as monotherapy and 1,520 patients received vildagliptin in combination with another medicinal product. 
Od tih je bolesnika njih 2264 primalo vildagliptin kao monoterapiju, a njih 1520 je primalo vildagliptin u kombinaciji s drugim lijekom.
Patients treated with vildagliptin reported significantly lower incidences of gastrointestinal adverse reactions versus those treated with metformin. 
Bolesnici liječeni vildagliptinom prijavili su značajno niže incidencije gastrointestinalnih nuspojava u odnosu na one liječene metforminom.
You should not use Jalra during pregnancy. 
Ne smijete uzimati Jalru tijekom trudnoće.
The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide). 
Primjena vildagliptina rezultira brzom i potpunom inhibicijom aktivnosti DPP-4, koja dovodi do povišene endogene razine natašte i postprandijalno inkretinskih hormona GLP-1 (glukagonu sličan peptid 1) i GIP (inzulinotropni polipeptid ovisan o glukozi).
Vildagliptin is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control. 
Vildagliptin je također indiciran za uporabu u kombinaciji s inzulinom (sa ili bez metformina) kad prehrana i tjelovježba povrh stabilne doze inzulina ne omogućuju odgovarajuću kontrolu glikemije.
Vildagliptin, a member of the islet enhancer class, is a potent and selective DPP-4 inhibitor. 
Vildagliptin, pripadnik skupine stimulatora Langerhansovih otočića gušterače, jaki je i selektivni DPP-4 inhibitor.
No dose adjustments are necessary in elderly patients (see also sections 5.1 and 5.2). 
U starijih bolesnika nije potrebno prilagođavati dozu (vidjeti također dijelove 5.1 i 5.2).
Your doctor will prescribe Jalra either alone or together with certain other antidiabetic medicines which you will already be taking, if these have not proved sufficiently effective to control diabetes. 
Liječnik će Vam propisati Jalru bilo kao monoterapiju ili u kombinaciji s nekim drugim lijekovima za liječenje šećerne bolesti koje već uzimate ako se ti drugi lijekovi nisu pokazali dostatno djelotvornima u kontroli šećerne bolesti.
Combination with ACE-inhibitors 
Kombinacija s ACE inhibitorima
Combination with pioglitazone, metformin and glyburide 
Kombinacija s pioglitazonom, metforminom i gliburidom
Following oral administration in the fasting state, vildagliptin is rapidly absorbed, with peak plasma concentrations observed at 1.7 hours. 
Nakon peroralne primjene natašte vildagliptin se brzo apsorbira pri čemu su vršne koncentracije u plazmi zapažene nakon 1,7 sati.
The exposure to vildagliptin after a single dose in patients with mild and moderate hepatic impairment was decreased (20% and 8%, respectively), while the exposure to vildagliptin for patients with severe impairment was increased by 22%. 
Izloženost vildagliptinu nakon jednokratne doze u bolesnika s blagim i umjerenim oštećenjem jetre bila je smanjena (20%, odnosno 8%), dok je izloženost vildagliptinu u bolesnika s teškim oštećenjem bila povećana za 22%.
Jalra works by making the pancreas produce more insulin and less glucagon. 
Jalra djeluje tako da gušterača stvara više inzulina, a manje glukagona.
In healthy elderly subjects (≥ 70 years), the overall exposure of vildagliptin (100 mg once daily) was increased by 32%, with an 18% increase in peak plasma concentration as compared to young healthy subjects (18-40 years). 
U zdravih starijih ispitanika (≥70 godina) ukupna izloženost vildagliptinu (100 mg jedanput na dan) bila je povećana za 32%, uz 18%-tni porast vršne koncentracije u plazmi u usporedbi s mladim zdravim ispitanicima (18-40 godina).
Adverse reactions reported in patients who received Jalra in double-blind studies as monotherapy and add-on therapies are listed below for each indication by system organ class and absolute frequency. 
Nuspojave zabilježene u bolesnika koji su primali Jalru u dvostruko slijepim ispitivanjima kao monoterapiju i kao dodatnu terapiju navedene su niže za svaku indikaciju prema klasifikaciji organskih sustava i apsolutnoj učestalosti.
• 50 mg daily taken as one dose in the morning if you are taking Jalra with another medicine called a sulphonylurea. 
• 50 mg na dan, što se uzima kao jedna doza ujutro ako uzimate Jalru s drugim lijekom koji se zove sulfonilureja.
How long to take Jalra 
Koliko dugo uzimati Jalru
Decreased blood glucose 
niska razina glukoze u krvi
The pancreas makes both of these substances. 
Obje te tvari stvara gušterača.
When used as monotherapy, in combination with metformin, in combination with thiazolidinedione, in combination with metformin and a sulphonylurea, or in combination with insulin (with or without metformin), the recommended daily dose of vildagliptin is 100 mg, administered as one dose of 50 mg in the morning and one dose of 50 mg in the evening. 
Kada se primjenjuje kao monoterapija, u kombinaciji s metforminom, u kombinaciji s tiazolidindionom, u kombinaciji s metforminom i sulfonilurejom, ili u kombinaciji s inzulinom (sa ili bez metformina), preporučena dnevna doza vildagliptina je 100 mg, primijenjena kao jedna doza od 50 mg ujutro i jedna doza od 50 mg navečer.
A clinical trial of vildagliptin in patients with New York Heart Association NYHA functional class I-III showed that treatment with vildagliptin was not associated with a change in left-ventricular function or worsening of pre-existing congestive heart failure (CHF) versus placebo. 
Kliničko ispitivanje vildagliptina u bolesnika s NYHA funkcionalnom klasom I-III pokazalo je da liječenje vildagliptinom nije povezano s promjenom u funkciji lijeve klijetke ili pogoršanjem već postojećeg kongestivnog zatajenja srca (KZS) u usporedbi s placebom.
AUC of the metabolites LAY151 and BQS867 increased on average about 1.5, 3 and 7-fold in patients with mild, moderate and severe renal impairment, respectively. 
AUC metabolita LAY151 i BQS867 povećao se u prosjeku oko 1,5; 3 odnosno 7 puta u bolesnika s blagim, umjerenim odnosno teškim oštećenjem bubrega.
Jalra 50 mg tablets 
Jalra 50 mg tablete
Another two-year carcinogenicity study was conducted in mice at oral doses up to 1,000 mg/kg. 
Druga je dvogodišnja studija kancerogenosti provedena na miševima s oralnim dozama do 1000 mg/kg.
No studies on the effect on human fertility have been conducted for Jalra (see section 5.3). 
Nisu provedena nikakva ispitivanja o učinku Jalre na plodnost u ljudi (vidjeti dio 5.3).
Results from studies conducted with these oral antidiabetics have shown no clinically relevant pharmacokinetic interactions. 
Rezultati ispitivanja provedenih s ovim oralnim antidijabeticima nisu pokazali klinički značajne farmakokinetičke interakcije.
Liver function should be monitored during treatment with Jalra at three-month intervals during the first year and periodically thereafter. 
Jetrenu funkciju treba pratiti tijekom liječenja Jalrom u razmacima od tri mjeseca tijekom prve godine liječenja te povremeno nakon toga.
Table 8 Key efficacy results of vildagliptin in placebo-controlled monotherapy trials and in add-on combination therapy trials (primary efficacy ITT population) 
Tablica 8 Ključni rezultati djelotvornosti vildagliptina u placebo kontroliranim ispitivanjima monoterapije i u ispitivanjima kombinirane terapije kao dodatak drugom lijeku (primarna djelotvornost u populaciji svih randomiziranih ispitanika)
(type A) and magnesium stearate. 
i magnezijev stearat.
Clinical studies performed with healthy subjects have shown no clinically relevant pharmacokinetic interactions. 
Klinička ispitivanja provedena na zdravim ispitanicima nisu pokazala klinički značajne farmakokinetičke interakcije.
Jalra 50 mg tablets are available in packs containing 7, 14, 28, 30, 56, 60, 90, 112, 180 or 336 tablets and in multipacks comprising 3 cartons, each containing 112 tablets. 
Jalra 50 mg tablete su dostupne u pakiranjima koja sadrže 7, 14, 28, 30, 56, 60, 90, 112, 180 ili 336 tableta i u višestrukim pakiranjima koja sadrže 3 kutije, a svaka sadrži 112 tableta.
Vildagliptin was associated with fewer hypoglycaemic events (0.7%) than gliclazide (1.7%). 
Vildagliptin je bio povezan s manje hipoglikemijskih događaja (0,7%) nego gliklazid (1,7%).
As monotherapy - in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. 
Kao monoterapija - u bolesnika čija se bolest ne može kontrolirati samo dijetom i tjelovježbom i za koje je metformin neprikladan zbog kontraindikacija ili nepodnošenja.
In patients with moderate or severe renal impairment or with end-stage renal disease (ESRD), the recommended dose of Jalra is 50 mg once daily (see also sections 4.4, 5.1 and 5.2). 
U bolesnika s umjerenim ili teškim oštećenjem bubrega ili u bolesnika u završnoj fazi bubrežne bolesti preporučena doza Jalre je 50 mg jedanput na dan (vidjeti također dijelove 4.4, 5.1 i 5.2).
It is not known if Jalra passes into breast milk. 
Nije poznato prelazi li Jalra u majčino mlijeko.
This helps to control the blood sugar level. 
To pomaže u kontroliranju razine šećera u krvi.
In this patient population, vildagliptin 100 mg daily was no more effective than vildagliptin 50 mg once daily. 
U ovoj populaciji bolesnika, doza od 100 mg vildagliptina na dan nije bila učinkovitija od doze od 50 mg vildagliptina jedanput na dan.
Jalra 50 mg tablets vildagliptin 
Jalra 50 mg tablete vildagliptin
Jalra should not be used in patients with hepatic impairment, including patients with pre-treatment alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3x the upper limit of normal (ULN) (see also sections 4.4 and 5.2). 
Jalra se ne smije primjenjivati u bolesnika s oštećenjem jetre, uključujući bolesnike u kojih su vrijednosti alanin aminotransferaze (ALT) ili aspartat aminotransferaze (AST) prije početka liječenja bile >3x vrijednosti gornje granice normale (GGN) (vidjeti također dijelove 4.4 i 5.2).
• Inflammation of the pancreas (pancreatitis) (frequency not known): Symptoms include severe and persistent pain in the abdomen (stomach area), which might reach through to your back, as well as nausea and vomiting. 
• Upala gušterače (pankreatitis) (učestalost nepoznata): simptomi uključuju jaku i upornu bol utrbuhu (područje trbuha), koja bi se mogla proširiti do leđa te mučninu i povraćanje.
The majority of adverse reactions in these trials were mild and transient, not requiring treatment discontinuations. 
U ovim je ispitivanjima većina nuspojava bila blaga i prolazna te nije bilo potrebno prekidati liječenje.
• 100 mg daily taken as 50 mg in the morning and 50 mg in the evening if you are taking Jalra alone, with another medicine called metformin or a glitazone, with a combination of metformin and a sulphonylurea, or with insulin. 
• 100 na dan, što se uzima kao doza od 50 mg ujutro i 50 mg navečer ako uzimate Jalru sam ili s drugim lijekom koji se zove metformin ili glitazon, u kombinaciji s metforminom i sulfonilurejom ili inzulinom.
Placebo-corrected mean change in HbA1c (%) at week 24 (95% CI) 
Placebo korigirana srednja promjena vrijednosti HbA1c (%) u 24. tjednu (95%CI)
Limited data from patients with end stage renal disease (ESRD) indicate that vildagliptin exposure is similar to that in patients with severe renal impairment. 
Ograničeni podaci dobiveni od bolesnika koji su u završnoj fazi bubrežne bolesti upućuju da je izloženost vildagliptinu slična onoj u bolesnika s teškim oštećenjem bubrega.
Study 2301: Vildagliptin 50 mg twice daily (N=90) Study 2384: Vildagliptin 50 mg twice daily (N=79) 
Ispitivanje 2301: vildagliptin 50 mg dvaput na dan (N=90) Ispitivanje 2384: vildagliptin 50 mg dvaput na dan (N=79)
Children and adolescents The use of Jalra in children and adolescents up to 18 years of age is not recommended. 
Djeca i adolescenti Jalra se ne preporučuje za primjenu u djece i adolescenata ispod 18 godina.
Mean baseline HbA1c (%) 
Srednja početna vrijednost HbA1c (%)
Overall, vildagliptin improved glycaemic control when given as monotherapy or when used in combination with metformin, a sulphonylurea, and a thiazolidinedione, as measured by clinically relevant reductions in HbA1c from baseline at study endpoint (see Table 8). 
Sveukupno, vildagliptin je poboljšao kontrolu glikemije kada je davan kao monoterapija, ili kada je primjenjivan u kombinaciji s metforminom, sulfonilurejom te tiazolidindionom, što je u ishodu ispitivanja izmjereno klinički značajnim smanjenjima vrijednosti HbA1c u odnosu na početne vrijednosti (vidjeti Tablicu 8).
• Common: Weight increase, swollen hands, ankle or feet (oedema) 
• Često: porast tjelesne težine, otečene šake, gležnjevi ili stopala (edem)
Combination with amlodipine, ramipril, valsartan or simvastatin 
Kombinacija s amlodipinom, ramiprilom, valsartanom ili simvastatinom
The effect of impaired hepatic function on the pharmacokinetics of vildagliptin was studied in patients with mild, moderate and severe hepatic impairment based on the Child-Pugh scores (ranging from 6 for mild to 12 for severe) in comparison with healthy subjects. 
Učinak oštećene jetrene funkcije na farmakokinetiku vildagliptina ispitivan je u bolesnika s blagim, umjerenim i teškim oštećenjem jetre, na temelju bodova prema Child-Pugh klasifikaciji (u rasponu od 6 za blagi do 12 za teški oblik) u usporedbi sa zdravim ispitanicima.
Vildagliptin is not metabolised by CYP 450 enzymes to any quantifiable extent. 
Vildagliptin se ne metabolizira enzimima CYP 450 do bilo kojeg mjerljivog opsega.
Should an increase in AST or ALT of 3x ULN or greater persist, withdrawal of Jalra therapy is recommended. 
Potraju li povišene vrijednosti AST-a ili ALT-a na razini 3x vrijednosti GGN-e ili većoj, preporučuje se prekinuti terapiju Jalrom.
As dual oral therapy in combination with - metformin, in patients with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin, - a sulphonylurea, in patients with insufficient glycaemic control despite maximal tolerated dose of a sulphonylurea and for whom metformin is inappropriate due to contraindications or intolerance, - a thiazolidinedione, in patients with insufficient glycaemic control and for whom the use of a thiazolidinedione is appropriate. 
Kao dvojna oralna terapija u kombinaciji s - metforminom, u bolesnika u kojih je kontrola glikemije nedostatna usprkos maksimalno podnošljivoj dozi metformina u monoterapiji, - sulfonilurejom, u bolesnika u kojih je kontrola glikemije nedostatna usprkos maksimalno podnošljivoj dozi sulfonilureje i za koje je metformin neprikladan zbog kontraindikacija ili nepodnošenja, - tiazolidindionom, u bolesnika u kojih je kontrola glikemije nedostatna i za koje je primjena tiazolidindiona prikladna.
When used in dual combination with a sulphonylurea, the recommended dose of vildagliptin is 50 mg once daily administered in the morning. 
Kada se primjenjuje u dvojnoj kombinaciji sa sulfonilurejom, preporučena doza vildagliptina iznosi 50 mg jedanput na dan, a daje se ujutro.
CARTON OF UNIT PACK 
KUTIJA ZA JEDINIČNO PAKIRANJE
Jalra contains lactose 
Jalra sadrži laktozu
In clinical trials, the magnitude of HbA1c reductions with vildagliptin was greater in patients with higher baseline HbA1c. 
U kliničkim je ispitivanjima stupanj redukcije HbA1c s vildagliptinom bio veći u bolesnika s većom početnom vrijednosti HbA1c.
• Very rare: Sore throat, runny nose, fever 
• Vrlo rijetko: grlobolja, curenje iz nosa, vrućica
• if you are taking an anti-diabetic medicine known as a sulphonylurea (your doctor may want to reduce your dose of the sulphonylurea when you take it together with Jalra in order to avoid low blood glucose [hypoglycaemia]). 
• ako uzimate lijek protiv šećerne bolesti iz skupine sulfonilureja (kako bi se izbjegle niske vrijednosti glukoze u krvi [hipoglikemija], Vaš će Vam liječnik možda smanjiti dozu sulfonilureje kad je uzimate zajedno s Jalrom).
There was no correlation between the severity of the hepatic disease and changes in the exposure to vildagliptin. 
Između težine bolesti jetre i promjena u izloženosti vildagliptinu nije bilo korelacije.
If a dose of Jalra is missed, it should be taken as soon as the patient remembers. 
Ako je bolesnik zaboravio uzeti dozu Jalre, treba je uzeti čim se sjeti.
When used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be considered to reduce the risk of hypoglycaemia. 
Kada se primjenjuje u kombinaciji sa sulfonilurejom, niža doza sulfonilureje se može razmotriti kako bi se smanjio rizik od hipoglikemije.
A multiple-dose, open-label trial was conducted to evaluate the pharmacokinetics of the lower therapeutic dose of vildagliptin (50 mg once daily) in patients with varying degrees of chronic renal impairment defined by creatinine clearance (mild: 50 to <80 ml/min, moderate: 30 to <50 ml/min and severe: <30 ml/min) compared to normal healthy control subjects. 
Otvoreno ispitivanje s višestrukim dozama bilo je provedeno kako bi se ocijenila farmakokinetika niže terapijske doze vildagliptina (50 mg jedanput na dan) u bolesnika s različitim stupnjevima kroničnog oštećenja bubrega definiranog klirensom kreatinina (blago: 50 do <80 ml/min, umjereno: 30 do <50 ml/min i teško: <30 ml/min) u usporedbi s normalnim zdravim kontrolnim ispitanicima.
Each tablet contains 50 mg vildagliptin. 
Svaka tableta sadrži 50 mg vildagliptina.
Liver function tests should be performed prior to the initiation of treatment with Jalra in order to know the patient's baseline value. 
Testove jetrene funkcije treba napraviti prije početka liječenja Jalrom kako bi se utvrdile početne vrijednosti.
In these cases, the patients were generally asymptomatic without clinical sequelae and liver function test results returned to normal after discontinuation of treatment. 
U tim slučajevima bolesnici su općenito bili bez simptoma i kliničkih posljedica, a testovi jetrene funkcije su se vratili na normalu nakon prekida liječenja.
• Frequency not known (cannot be estimated from the available data): Itchy rash, inflammation of the pancreas, localised peeling of skin or blisters, muscle pain 
• Učestalost nije poznata (učestalost se ne može procijeniti iz dostupnih podataka): osip koji svrbi, upala gušterače, lokalizirano ljuštenje kože ili mjehurići, bol u mišiću.
Driving and using machines If you feel dizzy while taking Jalra, do not drive or use machines. 
Ako osjećate omaglicu dok uzimate Jalru, nemojte upravljati vozilima niti raditi sa strojevima.
Accordingly, the metabolic clearance of vildagliptin is not anticipated to be affected by co-medications that are CYP 450 inhibitors and/or inducers. 
Zbog toga se ne očekuje da na metabolički klirens vildagliptina utječe istodobna primjena lijekova koji su inhibitori i/ili induktori CYP 450.
68.8% and 80.5% of the patients with moderate and severe renal impairment respectively were treated with insulin (mean daily dose of 56 units and 51.6 units respectively) at baseline. 
68,8% odnosno 80,5% bolesnika s umjerenim odnosno teškim oštećenjem bubrega bilo je liječeno inzulinom (srednja dnevna doza od 56 odnosno 51,6 jedinica) na početku.
Safety data were obtained from a total of 3,784 patients exposed to vildagliptin at a daily dose of 50 mg (once daily) or 100 mg (50 mg twice daily or 100 mg once daily) in controlled trials of at least 12 weeks duration. 
Podaci o sigurnosti dobiveni su na ukupno 3784 bolesnika koji su bili izloženi vildagliptinu u dnevnoj dozi od 50 mg (jedanput na dan) ili 100 mg (50 mg dvaput na dan ili 100 mg jedanput na dan) u kontroliranim kliničkim ispitivanjima koja su trajala najmanje 12 tjedana.
In the subgroups treated with insulin with or without concomitant metformin the placebo-adjusted mean reduction in HbA1c was -0.63% and -0.84%, respectively. 
U podskupinama liječenim inzulinom sa ili bez istodobne primjene metformina srednje sniženje HbA1c, prilagođeno s obzirom na placebo, bilo je -0,63% odnosno -0,84%.
There were more cardiac events in vildagliptin treated patients with NYHA class III heart failure compared to placebo. 
Bilo je više srčanih događaja u bolesnika sa zatajenjem srca NYHA klase III liječenih vildagliptinom u usporedbi s placebom.
• Common (may affect up to 1 in 10 people): Trembling, headache, dizziness, nausea, low blood glucose 
• Često (mogu se javiti u do 1 na 10 osoba): drhtanje, glavobolja, omaglica, mučnina, niska razina glukoze u krvi
In these trials, vildagliptin was administered as monotherapy in drugnaïve patients with type 2 diabetes or in combination in patients not adequately controlled by other antidiabetic medicinal products. 
U tim je ispitivanjima vildagliptin primjenjivan kao monoterapija u bolesnika sa šećernom bolešću tipa 2 koji još nisu primali lijekove za šećernu bolest, ili u kombinaciji u bolesnika u kojih nije bila postignuta odgovarajuća kontrola s drugim antidijabeticima.
Add-on / Combination studies Vildagliptin 50 mg twice daily + metformin (N=143) Vildagliptin 50 mg daily + glimepiride (N=132) Vildagliptin 50 mg twice daily + pioglitazone (N=136) Vildagliptin 50 mg twice daily + metformin + glimepiride (N=152) 
Ispitivanja lijeka kao dodatne terapije/kombinacije lijekova Vildagliptin 50 mg dvaput na dan + metformin (N=143) Vildagliptin 50 mg na dan + glimepirid (N=132) Vildagliptin 50 mg dvaput na dan + pioglitazon (N=136) Vildagliptin 50 mg dvaput na dan + metformin + glimepiridin (N=152)
Jalra should not be used during breast-feeding. 
Jalra se ne smije primjenjivati tijekom dojenja.
In these studies, vildagliptin was administered to more than 9,000 patients at daily doses of 50 mg once daily, 50 mg twice daily or 100 mg once daily. 
U tim je ispitivanjima vildagliptin primjenjivan u više od 9000 bolesnika u dnevnim dozama od 50 mg jedanput na dan, 50 mg dvaput na dan ili 100 mg jedanput na dan.
It is unknown whether vildagliptin is excreted in human milk. 
Nije poznato izlučuje li se vildagliptin u majčino mlijeko u ljudi.
Mean reductions were -1.20% with vildagliptin and -1.48% with rosiglitazone in patients with mean baseline HbA1c of 8.7%. 
Srednje vrijednosti sniženja bile su -1,20% za vildagliptin i -1,48% za roziglitazon u bolesnika sa srednjom početnom vrijednošću HbA1c od 8,7%.
How to take Jalra • Swallow the tablets whole with some water. 
• Tablete progutajte cijele s malo vode.
There may be an increased risk of angioedema in patients concomitantly taking ACE-inhibitors. 
Može postojati povećani rizik od angioedema u bolesnika koji istodobno uzimaju ACE inhibitore (vidjeti dio 4.8).